IAS Towards an HIV Cure Symposium. Victoria University City Convention Center, Melbourne, Australia

Similar documents
2015 Towards an HIV Cure Symposium 18 & 19 July 2015 Hyatt Regency Hotel, Vancouver, Canada

State of the ART: HIV Cure where are we now and. where are we going? Jintanat Ananworanich, MD, PhD MHRP

MHRP. Outline. Is HIV cure possible? HIV persistence. Cure Strategies. Ethical and social considerations. Short video on patients perspectives on cure

Can HIV be cured? (how about long term Drug free remission?)

Approaching a Cure Daniel R. Kuritzkes, MD

S C I E N T I F I C P R O G R A M M E Last Update: 20/03/2013

With over 20 drugs and several viable regimens, the mo6vated pa6ent with life- long access to therapy can control HIV indefinitely, elimina6ng the

Dr Jintanat Ananworanich

The Towards an HIV Cure initiative would like to thank the following organizations for their generous support in 2015

Towards an HIV Cure. Steven G. Deeks Professor of Medicine University of California, San Francisco

Cent Gardes Conference: HIV Vaccines. Organized by Fondation Mérieux «Les Pensières» Fondation Mérieux Conference Center Veyrier du Lac - France

Comparison of latent HIV-1 reactivation in multiple cell model systems

Cent Gardes Conference: HIV Vaccines. Organized by Fondation Mérieux Les Pensières Center for Global Health Veyrier du Lac - France

Establishment and Targeting of the Viral Reservoir in Rhesus Monkeys

HIV Antibody Characterization for Reservoir and Eradication Studies. Michael Busch, Sheila Keating, Chris Pilcher, Steve Deeks

Epigenetic and Metabolic Regulation of Aging and Aging-Related Diseases

HIV Cure Update. Christine Durand, MD 14 de abril de 2016, XIII Conferência Brasil Johns Hopkins University em HIV/AIDS

IAS 2013 Towards an HIV Cure Symposium

Clinical HIV-1 eradication studies

BEAT-HIV Delaney Collaboratory to Cure HIV-1 Infection by Combination Immunotherapy

Impact of Vorinostat Treatment of Non- Hodgkin s Lymphoma on HIV-1 Latent Reservoir

HIV cure research: current strategies and challenges. current strategies to eliminate latently infected cells 2/10/2015

Identification and Characterization of CD4 T cells actively transcribing HIV RNA in Peripheral Blood

Inconsistent HIV reservoir dynamics and immune responses following anti-pd-1 therapy

T Memory Stem Cells: A Long-term Reservoir for HIV-1

Eradication of HIV infection Not in my lifetime? or Just around the Corner? Michael M. Lederman, MD

Recent Insights into HIV Pathogenesis and Treatment: Towards a Cure

Hot Topics in HIV. Barcelona 2018

IAS 2015 Towards an HIV Cure symposium Vancouver. Distinct HIV Genetic Populations in Effector Memory T Cells after Prolonged Therapy

HIV cure strategies: interventions, endpoints and ethics

Invited Review CROI 2018: Advances in Basic Science Understanding of HIV

HIV remission after discontinuing ART: is it achievable?

Destruction of the Residual Active HIV-1 Reservoir by Env-specific Immunotoxin

CTLA-4-expressing CD4 T cells are critical contributors to SIV viral persistence

CROI 2016 Review: Immunology and Vaccines

RESEARCH Towards. an HIV Cure RESER RVOIRS CURE CURE CURECURE. Symposium RESERVOIR INDUSTRY GLOBAL GLOBAL BAL GLOBAL RESEARCH RESEARCH INDUS

The HIV Cure Agenda. CHIVA Oct Nigel Klein. Institute of Child Health and Great Ormond Street Hospital, London, UK

HIV cure: current status and implications for the future

5/11/2017. HIV Cure Research Questions and a Few Answers

Functional cure of HIV: the scale of the challenge. *, David S. Khoury 1

In vivo analysis of HIV replication and persistence in the myeloid compartment

HHS Public Access Author manuscript Nat Med. Author manuscript; available in PMC 2017 February 23.

HIV remission: viral suppression in the absence of ART. Sarah Fidler Brian Gazzard Lecture BHIVA 2016

cure research HIV & AIDS

"Development and Clinical Progress. of DNA Vaccines" Program

IAS 2015 Towards an HIV Cure symposium Vancouver Immune recognition following latency reversal

IAS 2016 Towards an HIV Cure Symposium Durban, South Africa.

Registration Continental Breakfast. Histone Modifications and Cancer- Part 1

Working Group#1: Trial Endpoints, Biomarkers & Definitions

DNA and Protein Vaccination Confers Protection Upon Mucosal Challenge with Heterologous SIVsmE660 (OA 10.04)

Targeting latent HIV infection: on the road towards an HIV Cure

Early Antiretroviral Therapy

Inves&gación básica y curación del VIH-1

HIV and Cancer Curative Approaches Cross-disciplinary research. Steven Deeks, MD Professor of Medicine University of California, San Francisco

Combined IL-21 and IFNα treatment limits inflammation and delay viral rebound in ART-treated, SIV-infected macaques

Should There be Further Efficacy Testing of T-T cell Based Vaccines that do not Induce Broadly Neutralizing Antibodies?

Pediatric HIV Cure Research

Novel Approaches for the Assessment of the In Vivo Residual Virus Pool and Viral Eradication Strategies in SIV-infected Rhesus Macaques

Immunoreceptors and Immunotherapy

Residual Cancer. May 3-5, International Symposium. on Minimal. Le Corum. > Preliminary. Program MONTPELLIER, FRANCE

HIV Pathogenesis and Natural History. Peter W. Hunt, MD Associate Professor of Medicine University of California San Francisco

A VACCINE FOR HIV BIOE 301 LECTURE 10 MITALI BANERJEE HAART

IAS Towards an HIV Cure Symposium: people focused, science driven July 2015, Vancouver, Canada

The potential role of PD-1/PD-L1 blockade in HIV Remission and Cure Strategies

CORSO DI AGGIORNAMENTO E.C.M.

PERSPECTIVES. Towards an HIV cure: a global scientific strategy

HIV transcription, Tat transactivation mrna processing and latency

Complete Transcriptome Analysis of Latently Infected CD4 + T Cells

Pathogenesis Update Robert F. Siliciano, MD, PhD

Professor Andrew McMichael

HIV Reservoirs in Developing Countries: Implication for HIV CURE Strategies

Asier Sáez-Cirión, PhD Unité de Régulation des Infections Rétrovirales Institut Pasteur, Paris, France

Determinants of Immunogenicity and Tolerance. Abul K. Abbas, MD Department of Pathology University of California San Francisco

Newsletter. August 7, Visit

DEBATE ON HIV ENVELOPE AS A T CELL IMMUNOGEN HAS BEEN GAG-GED

Professor Jonathan Weber

T Cell Activation, Costimulation and Regulation

Module R: Recording the HIV Reservoir

Interleukin-21 combined with ART reduces inflammation and viral reservoir in SIV-infected macaques

PROGRAM RNA The Nineteenth Annual Meeting of the RNA Society Quebec City, Canada June 03 08, 2014

Perspective HIV Infection: Advances Toward a Cure

Inves)gación básica y curación del VIH- 1

SYSTEMS BIOLOGY APPROACHES TO IDENTIFY MECHANISMS OF IMMUNE MEDIATED PROTECTION TRANSLATING RESEARCH INTO HEALTH

COMPLETE PRESS CONFERENCE SCHEDULE

HIV Eradication and the Quest for Functional Cure

Novel Heterologous Prime-Boost Vaccine Strategies for HIV. Dan Barouch April 18, 2012

9/29/2014. Patterns of hepatitis C virus RNA levels during acute infection: the InC 3 study. Background. Background. Background

Richard Jefferys Basic Science, Vaccines & Cure Project Director Treatment Action Group NASTAD Prevention and Care Technical Assistance Meeting

23 rd CROI Report Back AETC/Community Consortium Harry W. Lampiris, MD Professor of Clinical Medicine, UCSF Chief, ID Section, Medical Service,

GLOBAL INVESTMENT IN HIV CURE RESEARCH AND DEVELOPMENT IN 2017 AFTER YEARS OF RAPID GROWTH FUNDING INCREASES SLOW

Toward an HIV Cure Symposium Meeting Report

FOCIS goes South: ADVANCES IN TRANSLATIONAL AND CLINICAL IMMUNOLOGY

Induction and Clearance of Latent HIV Infection:

Human Immunodeficiency Virus

The Third D: Long Term Solutions to End the Epidemic. Mitchell Warren Executive Director, AVAC 12 February 2014

CROI 2013: Basic Science Review

Additional Presentation Demonstrates Potential Mechanisms for Unprecedented HIV Reservoir Depletion by SB-728-T

Inhibition of HIV-1 Integration in Ex Vivo-Infected CD4 T Cells from Elite Controllers

Innovation and Promise in Epilepsy Research 3 rd International UCI EpiCenter Symposium

PRELIMINARY PROGRAM. Sharon Chen David Ellis Debbie Marriott Orla Morrissey Monica Slavin

Transcription:

IAS Towards an HIV Cure Symposium 19 th - 20 th 2014 Victoria University City Convention Center, Melbourne, Australia 19th Saturday 19th 8:30-9:00 Registration Opening 9:00-9:30 Welcome and Introduction Françoise Barré-Sinoussi, Institut Pasteur and Inserm Jack Whitescarver, Office of AIDS Research, National Institutes of Health Chair: Sharon Lewin, The Alfred Hospital, Monash University & Burnet Institute Welcome Remarks Hon. David Davis, Minister for Health, Victorian Government Keynote 9:30-10:00 Chair: Steve Deeks, University of California, San Francisco The Role of Therapeutic Vaccination in HIV Cure Strategies Jeff Lifson, Frederick National Laboratory for Cancer Research Session 1 10:00-11:20 Clearing HIV-Infected Cells: Kill Chairs: Asier Saez-Cirion, Institut Pasteur and Marcus Altfeld, Heinrich Pette Institute IS1-1 10:00-10:20 Allogeneic Stem Cell Transplantation, Graft-versus-Host Disease and the Elimination of HIV Invited Speaker: Geoff Hill, Queensland Institute of Medical Research OA1-1 10:20-10:35 OA1-2 10:35-10:50 A population of CD8 T cells is located in germinal centers that is functionally capable of mediating bispecific antibody mediated killing of HIV-infected T cells Richard Koup, Vaccine Research Center Potent and broadly anti-hiv-1 neutralizing antibody VRC01 inhibits HIV-1 transmission from plasmacytoid dendritic cells to CD4 T lymphocytes Bin Su, Inserm

19th OA1-3 10:50-11:05 HIV Controller CD4+ T cells preferentially express a public TCR clonotype that confers high avidity responses against Gag Lisa A. Chakrabarti, Institut Pasteur OA1-4 11:05-11:20 Follicular SIV-specific CD8 T cells contribute to enhanced control Rama Rao Amara, Emory University 11:20-11:45 Coffee Break Session 2 11:45-13:05 Reversing Latent HIV : Shock Chairs: Mathias Lichterfeld, Massachusetts General Hospital and Ben Berkhout, University of Amsterdam IS2-1 11:45-12:05 Epigenetic Regulation of HIV Latency Invited Speaker: Melanie Ott, Gladstone Institutes and University of California, San Francisco OA2-1 12:05-12:20 Synergistic activation of HIV-1 expression by compounds releasing active positive transcription elongation factor b (P-TEFb) and by inducers of the NF-kB signaling pathway Gilles Darcis, Université Libre de Bruxelles and Université de Liège OA2-2 12:20-12:35 OA2-3 12:35-12:50 A new family of compounds that reactivate latent HIV in central memory T cells Vicente Planelles, University of Utah Induction and clearance of latent HIV infection : modeling viral clearance by immune effectors using cells from ART-treated patients David Margolis, University of North Carolina at Chapel Hill OA2-4 LB 12:50-13:05 The HDAC Inhibitor Romidepsin is Safe and Effectively Reverses HIV-1 latency in vivo as Measured by Standard Clinical Assays Ole Søgaard, Aarhus University Hospital 13:05-14:00 Lunch Break

19th NADS1 14:00-15:00 Roundtable: Analytical Treatment Interruption in HIV Cure Research Chair: Edwina Wright, The Alfred Hospital, Monash University & Burnet Institute Panelists: Judith Auerbach, University of California, San Francisco Giulio Maria Corbelli, European AIDS Treatment Group Daniel Kuritzkes, Brigham and Women s Hospital Lars Østergaard, Aarhus University Hospital Jeremy Sugarman, Johns Hopkins Berman Institute of Bioethics Session 3 15:00-16:35 Why Does HIV Persist on ART? Chairs: Daniel Douek, Vaccine Research Center, NIAID, NIH and Sarah Read, Division of AIDS, NIAID, NIH IS3-1 15:00-15:20 Therapeutic Efficacy of Neutralizing Antibodies for HIV Invited Speaker: Dan Barouch, Beth Israel Deaconess Medical Center and Ragon Institute of MGH, MIT and Harvard OA3-1 15:20-15:35 Genetically characterizing the role of cell proliferation in maintaining persistent HIV during effective HIV therapy Sarah Palmer, Westmead Millennium Institute and University of Sydney OA3-2 15:35-15:50 TLR2 stimulation promotes HIV-1 infection of CD4+ T cells by increasing the susceptibility of CCR6- T cells to infection Jean-François Buldoc, Université Laval OA3-3 15:50-16:05 Interleukin-21 improves reconstitution of intestinal Th17 and Th22 cells and reduces residual inflammation in ART-suppressed SIV-infected Rhesus Macaques Mirko Paiardini, Emory University OA3-4 LB 16:05-16:20 Cryptic transcription of HIV-RNA species from defective proviruses: A novel pathway for persistent immune activation in patients with HIV-1 infection and mechanism for persistent seropositivity despite undetectable levels of virus Hiromi Imamichi, NIAID/NIH OA3-5 LB 16:20-16:35 IL-7 increases HIV-1 proviral integration in CD4+ T cells by inducing SAMHD1 phosphorylation, which can be blocked by Lck and PKC inhibitors Maria Teresa Coiras, Instituto de Salud Carlos III 16:35-18:00 Poster Exhibition & Networking Session

20th Sunday 20th NADS2 9:30-10:30 Roundtable: Preparedness for HIV Cure in Resource-Limited Settings Chair: Paula Munderi, MRC/UVRI Uganda Research Unit on AIDS Panelists: Jintanat Ananworanich, US Military HIV Research Program Robert Murphy, Northwestern University Kenly Sikwese, Positive Health Outcomes Mathurin Tejiokem, Pasteur Centre of Cameroon Joseph Tucker, UNC Project-China 10:30-11:00 Coffee Break Session 4 11:00-12:50 Where Does HIV Persist on ART? Chairs: Luis Montaner, The Wistar Institute and Melissa Churchill, Burnet Institute IS4-1 11:00-11:20 Impact of antiretroviral treatment on HIV reservoirs Invited Speaker: Christine Rouzioux, Université Paris Descartes OA4-1 11:20-11:35 The immune checkpoint blockers PD-1, LAG-3 and TIGIT are biomarkers of HIV infected cells during ART and identify distinct cellular reservoirs Remi Fromentin, VGTI Florida OA4-2 11:35-11:50 OA4-3 11:50-12:05 Following in vitro culture with myeloid dendritic cells, negative regulators of T-cell activation are expressed preferentially on latently infected CD4+ T-cells Vanessa A. Evans, Monash University and Burnet Institute Ultra-deep barcoded SIVmac239 to identify and quantify viral reservoirs and recrudescent viremia Brandon Keele, Frederick National Laboratory OA4-4 12:05-12:20 In vivo analysis of HIV replication and persistence in the myeloid compartment Rae Ann Spagnuolo, University of North Carolina at Chapel Hill

20th OA4-5 12:20-12:35 Simian Immunodeficiency Virus (SIV) infection of the macaque testis- An immune privileged site Wendy Winnall, University of Melbourne OA4-6 LB 12:35-12:50 A novel assay that precisely measures the size of the latent HIV reservoir reveals that ART-naïve individuals harbour a large pool of latently infected CD4+ T cells Nicolas Chomont, VGTI Florida 12:50-14:00 Lunch Break & Poster Exhibition NADS3 14:00-14:30 Roundtable: Public and Private Partnerships in HIV Cure Research Chairs: Sharon Lewin, The Alfred Hospital, Monash University and Burnet Institute, and Zhi Hong, GlaxoSmithKline Panelists: David Kaslow, PATH Mike McCune, University of California, San Francisco Closing 14:30-15:00 Chair: Carl Dieffenbach, NIH, NIAID Keynote: Targeting chromatin remodelling as a treatment for haematogical malignancies lessons we can learn for the treatment of latent HIV Miles Prince, Peter MacCallum Cancer Centre 15:00-15:15 IAS-ANRS HIV Cure Young Investigator Prize Ceremony Chair: Jean-François Delfraissy, ANRS 15:15-15:30 Closing Remarks

2014 Towards an HIV Symposium International AIDS Society 19 & 20 2014 Victoria University, City Convention Center, 300 Flinders Street, Melbourne, Australia TIME Saturday 19th Sunday 20th TIME 30 8:30-9:00 Registration 30 9:00-9:30 Welcome Remarks Victoria Health Minister, David Davis MP 1h 35 1h 55 1h 20 25 1h 20 30 9:30-10:00 10:00-11:20 11:20-11:45 11:45-13:05 Break 9:30-10:30 Lunch Break 13:05-14:00 Lunch Poster Exhibition 12:50-14:00 14:00-15:00 15:00-16:35 Keynote Address Jeff Lison S1: Clearing HIV-infected Cells: Kill Invited Speaker: Geoff Hill S2: Reversing Latent HIV: Shock Invited Speaker: Melanie Ott Roundtable: Analytical Treatment Interruprion in HIV Cure Research S3: Why Does HIV Persist on ART? Invited Speaker: Dan Barouch Roundtable: Preparedness for HIV Cure in Resource-Limited Settings Break S4: Where Does HIV Persist on ART? Invited Speaker: Christine Rouzioux Discussion: Public-Private Partnership for HIV Cure Closing Session & IAS/ANRS Young Investigator Prize Invited Speaker: Miles Prince 10:30-11:00 11:00-12:50 14:00-14:30 14:30-15:30 1h 30 1h 50 1h 10 30 1h 1h 25 16:35-18:00 Poster Exhibition